SeaStar Medical Holding Corporation (NASDAQ:ICU) Short Interest Down 22.7% in August

SeaStar Medical Holding Corporation (NASDAQ:ICU) was the recipient of a large drop in short interest during the month of August. As of August 15th, there was short interest totaling 1,600,000 shares, adropof22.7% from the July 31st total of 2,070,000 shares. Based on an average daily volume of 7,460,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately6.0% of the shares of the company are short sold. Approximately6.0% of the shares of the company are short sold. Based on an average daily volume of 7,460,000 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Investors Weigh In On SeaStar Medical

A number of large investors have recently made changes to their positions in the company. Tyche Wealth Partners LLC bought a new position in shares of SeaStar Medical during the 1st quarter valued at approximately $63,000. XTX Topco Ltd raised its stake in SeaStar Medical by 395.4% during the 2nd quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock valued at $26,000 after purchasing an additional 48,674 shares during the period. Finally, Armistice Capital LLC purchased a new stake in SeaStar Medical during the 1st quarter valued at approximately $1,018,000. 1.69% of the stock is currently owned by institutional investors.

SeaStar Medical Stock Up 0.1%

Shares of ICU stock opened at $0.84 on Tuesday. The firm has a market capitalization of $23.40 million, a PE ratio of -0.32 and a beta of -1.00. The company has a 50 day moving average price of $0.74 and a 200-day moving average price of $1.15. SeaStar Medical has a 52 week low of $0.31 and a 52 week high of $5.79.

SeaStar Medical (NASDAQ:ICU) last issued its earnings results on Wednesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.25. The company had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $0.25 million.

Analysts Set New Price Targets

Separately, Wall Street Zen raised SeaStar Medical from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.